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Increased prefrontal cortex 
interleukin-2 protein levels 
and shift in the peripheral t 
cell population in progressive 
supranuclear palsy patients
Rasmus Rydbirk  1, Betina Elfving2, Jonas Folke  1, Bente pakkenberg1,3, Kristian Winge3,4, 
tomasz Brudek  1 & susana Aznar1
Accumulating evidence suggests neuroinflammation to be an integrated feature of neurodegeneration. 
Profiling inflammatory mediators across diseases may reveal common and disease-specific signatures. 
Here, we focused on progressive supranuclear palsy (PSP), a tauopathy presenting motor and cognitive 
dysfunction. We screened for 21 cytokines and growth factors in the dorsomedial prefrontal cortex 
of 16 PSP and 16 control brains using different quantitative techniques. We found and validated 
increased interleukin (IL)-2 protein levels in the PSP group expressed locally by neurons and glia cells. 
We further investigated central players in neuroinflammatory pathways and found increased mRNA 
expression of glycogen synthase kinase 3 beta (GSK3B). IL-2 and GSK3B proteins are T and natural killer 
(NK) cell regulators and have previously been associated with other neurodegenerative diseases such 
as Alzheimer’s disease, Parkinson’s disease and multiple system atrophy. In addition, we identified 
a shift in peripheral CD4+ and CD8+ t cell populations toward increased numbers of memory and 
reduced numbers of naive T cells. We also observed increased numbers of CD56+ NK cells, but not of 
CD56+CD57+ or CD57+ NK cells. Our findings suggest a role for IL-2 in PSP disease processes and point 
toward active and possibly dysfunctional peripheral immune responses in these patients.
Progressive supranuclear palsy (PSP) is a progressive, neurodegenerative disease that shares clinical features with 
other parkinsonian disorders and Alzheimer’s disease (AD)1. Neuropathologically, PSP is characterized by accu-
mulation of tau protein in neurofibrillary tangles (NFT) in tufted astrocytes. The highest load of NFTs are local-
ized in different areas of the basal ganglia and the brainstem, but cortical areas including the frontal lobe are also 
affected2,3. Brain imaging studies have shown that brain atrophy in PSP patients is accompanied by microglial 
activation in the frontal cortex4,5. This suggests that neuroinflammatory processes are part of the course of the 
disease. Still, there is a knowledge gap regarding how neuroimmunomodulating factors are affected in PSP brains. 
The few existing studies approaching this topic have focused solely on gene expression without reporting protein 
levels6,7. This information is important, not only for understanding the pathophysiology behind this disease, but 
also for illustrating to what extend neuroinflammatory processes are a common manifestation in neurodegener-
ative diseases. To our knowledge, no study has investigated the immune cell profile in PSP patients to shed light 
on the possible involvement of the peripheral immune system in PSP.
The primary aim of the present study was to investigate the neuroinflammatory signaling profile in the dor-
somedial prefrontal cortex (dmPFC) of PSP patients. Using multiplex assays, we screened for protein levels of 
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21 cytokines and growth factors in post-mortem brain samples from 16 PSP patients and 16 normal controls 
(NCs). Significant differences were validated using sensitive electrochemiluminescence technology. To depict the 
underlying processes associated with cytokine aberrancies, we performed quantitative gene expression analyses of 
up- and down-stream targets as well as of signaling effector molecules. Lastly, using flow cytometry we screened 
for peripheral changes in CD4+ and CD8+ T cell, and NK cell numbers in PSP patients.
Results
IL-2 protein levels are increased in PSP patients. Of the 21 protein targets, IL-2 (F(4,15) = 7.931, 
p = 0.001, R2 = 0.68) and G-CSF (F(4,11) = 16.141, p < 0.001, R2 = 0.85) passed the correction for multiple test-
ing, and both cytokines were predicted by group (t = 3.888, p = 0.002 and t = −7.819, p < 0.001, respectively). 
We then validated these findings using a more sensitive singleplex assay. The observed differences in G-CSF 
protein levels did not pass validation (F(4,11) = 0.501, p > 0.050, R2 = 0.25) but we confirmed differences in 
IL-2 protein levels (F(4,23) = 3.698, p = 0.018, R2 = 0.39; Fig. 1A). PSP patients showed increased IL-2 protein 
levels (t = 3.425, p = 0.002), while in general, males showed lower levels than females (t = −2.804, p = 0.010). 
Scores for the presence of dementia and resting tremor (Table 1) within the first year of diagnosis correlated with 
Luminex measurements of IL-2 protein levels (Spearman’s rho(ρ) = −0.881, p < 0.001, and ρ = 0.798, p = 0.006, 
respectively; Supplementary Fig. S3), with dementia scores showing a negative correlation whereas tremor scores 
showed a positive correlation. Conversely, no correlations were found with MSD measurements of IL-2 protein 
levels (p > 0.050; Supplementary Fig. S3). No other clinical scores correlated significantly to IL-2 protein levels 
(p > 0.050; data not shown).
Figure 1. Interleukin-2 (IL-2) and glycogen synthase kinase 3 beta (GSK3B) levels. (A) IL-2 protein levels in 
progressive supranuclear palsy (PSP) patients normalized to normal control (NC) levels. Protein levels were 
measured using two commercial assays based on Luminex or MSD technology. Filled symbols mark male 
subjects, open symbols mark female subjects. (B) mRNA levels of GSK3B. Expression levels normalized to the 
reference genes ubiquitin-conjugating enzyme 2D2 (UBE2D2), ribosomal protein 13a (RPL13A) and DNA 
topoisomerase 1 (TOP1). Data presented as mean ± SEM. *p < 0.050; **p < 0.010. (C) Immunofluorescent 
stainings of IL-2 (red), and NeuN (green) or (D) GFAP (green). Nuclei are stained with DAPI (blue). Scale bars: 
20 µm, 100X magnification.
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GSK3B mRNA levels are increased in PSP patients. We then measured mRNA levels of central pro-
tein players in inflammatory pathways (Table 2). We identified increased mRNA levels of GSK3B in PSP patients 
(F(5,17) = 4.845, p = 0.006, R2 = 0.59; Fig. 1B) which was predicted by group (t = 3.914, p = 0.001) and RIN 
(t = −2.200, p = 0.042). Further, investigating downstream targets to GSK3B, only the PD-related NR4A2 was 
significantly described by our model (F(5,13) = 4.413, p = 0.014), but only by RIN (t = −2.973, p = 0.011) and not 
Patient ID 1 2 3 4 5 6 7 8 9 10 11 12 13
Disease duration (years) 5 8 5.5 8 10 5 9 9 6 10 12 7 12
Gaze palzy at onset Yes Yes Yes Yes No Yes No Yes Yes No No Yes Yes
Dementia* No Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes
Cognitive dysfunction*a + +++ + ++ +++ ++ + + +++ ++ +++ + +++
Apathy*a + − − + +++ − − − +++ − + + −
Speech impairment*a + +++ ++ + ++ + ++ +++ ++ + + +++ +++
Sleep problems*a ++ ++ + ++ + ++ +++ +++ +++ − ++ ++ ++
Nocturia*a ++ ++ ++ ++ ++ ++ ++ ++ +++ − +++ +++ +
Response to L-DOPA*b + − + − + − ++ + − − ++ + +
Resting tremor* Yes No No No No No Yes No No Yes No No No
Axial rigidity*a + ++ ++ + + + +++ + + + + + ++
Bradykinesia*a + + ++ ++ +++ +++ + + +++ + ++ +++ +++
Postural instability at onset Yes Yes Yes Yes Yes Yes Yes Yes No No Yes Yes No
Diagnosis PSP-P PSP-RS PSP-RS PSP-RS PSP-F PSP-RS PSP-P PSP-SL PSP-F PSP-RS PSP-P/RS PSP-P/RS PSP-F
Table 1. Clinical characteristics of the PSP patients. Data are shown for the samples donated by Bispebjerg 
Brain Bank, from which medical records were available. *Based on the first year after diagnosis; a+: 
Diminishable, ++: Some, +++: Intense; b+: Poor, ++: Good; PSP-P: PSP with parkinsonism resembling 
Parkinson’s disease; PSP-RS: PSP with Richardson’s syndrome; PSP-F: PSP with frontal lobe cognitive or 
behavioural presentations; PSP-SL: PSP with speech or language disorders1.
Protein
NC PSP Model statistics
Mean SD Mean SD p R2
bFGF 1132.843 337.960 960.472 387.762 0.470# 0.14
G-CSF 58.583 15.971 20.261 6.811 <0.001# 0.85
G-CSF (M) 22.810 21.688 11.726 7.201 0.501 0.24
GM-CSF 43.147 9.401 46.913 5.573 0.344# 0.20
IFN-γ 13.254 6.149 14.040 6.301 0.583# 0.23
IL-1β 1.906 0.999 1.692 1.243 0.038#* 0.43
IL-2 3.377 1.320 5.675 0.951 0.001# 0.68
IL-2 (M) 1.479 0.283 1.670 0.157 0.018 0.39
IL-6 16.126 13.332 8.842 5.991 0.191# 0.34
IL-7 6.768 1.607 5.588 1.585 0.023#* 0.42
IL-13 1.232 0.330 0.893 0.159 0.015#* 0.44
MCP1 15.553 7.030 14.933 6.330 0.393# 0.19
MIP1β 2.107 0.617 1.727 0.400 0.360# 0.20
PDGF-BB 32.421 11.170 34.885 14.453 0.640# 0.10
mRNA Mean SD Mean SD p R2
GSK3B 0.403 0.228 1.066 0.682 0.006 0.59
NFKBIA 1.905 1.957 1.049 0.570 0.553 0.20
NR4A2 1.922 0.846 3.257 2.985 0.014 0.63
RELA 1.189 0.885 0.980 0.559 0.257 0.30
Table 2. Results from protein and mRNA measurements. All measurements are in pg/ml. bFGF: basic 
fibroblast growth factor; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte macrophage 
colony-stimulating factor; IFN-γ: interferon-kappa; IL-1β, -2, -6, -7, and -13: interleukin-1beta, -2, -6, -7, and 
-13, respectively; MCP1: monocyte chemoattractant protein 1; MIP1β: macrophage inflammatory protein 
1beta; PDGF-BB: platelet-derived growth factor-BB; GSK3B: glycogen synthase kinase 3 beta; NFKBIA: nuclear 
factor kappa(κ)-light-chain-enhancer of activated B cells inhibitor alpha; NR4A2: nuclear receptor subfamily 4 
group A member 2 (also known as Nurr1); RELA: NF-κB subunit p65; RET: receptor tyrosine kinase rearranged 
during transfection. *did not pass Bonferroni correction; (M) measured on MSD instrument; # subject to 
multiple comparison adjustment; R2 alignment with model.
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group (p > 0.050). Neither NFKBIA nor RELA, both immune regulatory factors, were significantly described by 
our model (p > 0.050).
IL-2 protein is expressed by NeuN+ and GFAP+ brain cells. To investigate if IL-2 is produced locally 
by brain cells, we performed double immunofluorescence labelling using specific antibodies against IL-2, neu-
ronal nuclei (NeuN), and glial fibrillary acidic protein (GFAP) on brain sections from both PSP patients and NCs. 
We observed co-localization of IL-2 with both NeuN and GFAP in both groups (Fig. 1C,D) confirming that IL-2 
is produced locally in the brain.
The number of peripheral T and NK cells are altered in blood of PSP patients. Lastly, using flow 
cytometry on a new cohort (18 NCs, nine PSP patients) we investigated whether the elevated levels of IL-2 in PSP 
brains could be reflected in the composition of peripheral T lymphocytes. We observed a significant increase 
in numbers of CD4+ T cells in PSP patients (t = 3.812, p < 0.001; Fig. 2B) accompanied by a shift in the ratio 
between memory and naive CD4+ T cells (t = 3.915, p < 0.001, and t = 7.940, p < 0.001, respectively; Fig. 2C,D). 
CD8+ T cells numbers did not differ between the groups (t = 1.602, p = 0.122; Fig. 2E), however, we also observed 
a shift in the ratio between memory and naive CD8+ T cells (t = 7.667, p < 0.001, and t = 8.595, p < 0.001, respec-
tively; Fig. 2F,G) in PSP patients. We did not see any differences in the levels of total T cells (t = 0.318, p = 0.754; 
Fig. 2A). Since IL-2 protein not only affects classical T cells but also interacts with different types of natural 
killer (NK) cells, we included NK cell markers in our setup. We saw no differences in the numbers of total NK 
cells (t = 1.071, p = 0.295; Fig. 2H) between the groups, however, CD56+ NK cell numbers were increased in 
PSP patients (t = 7.007, p < 0.001; Fig. 2I). We found a tendency towards increased CD57+ NK cells (t = 1.956, 
p = 0.062; Fig. 2K) whereas there was no difference in CD56+CD57+ NK cells (t = 0.699, p = 0.491; Fig. 2J).
Discussion
To our knowledge, this is the first study extensively evaluating cytokine protein levels in brains affected by PSP. 
We screened for 18 cytokines and three growth factors and identified increased IL-2 protein levels in the pre-
frontal cortex of the brain in PSP patients. Generally, the effects of IL-2 are maturation and survival of T cells 
of the peripheral immune system8. However, the expression of IL-2 and IL-2 receptors is found in brain cells, 
and we have previously shown how NeuN+ cells express IL-2 protein in both healthy brains, and brains from 
patients diagnosed with Parkinson’s disease or multiple system atrophy9. Concordantly, in this study we observed 
co-localization of IL-2 inside both NeuN+ and GFAP+ cells. IL-2 protein has been suggested to be a neurokine10. 
Hence, the increase in IL-2 protein levels could be of neuronal origin and caused by disease processes. In the cur-
rent study, for IL-2 protein levels, we observed both sex-specific differences and correlations to clinical scores. To 
our knowledge, no study has identified sex-specific differences in PSP, nor does the incidence rate differ between 
sexes11. The correlations to the clinical scores were significant for the Luminex measurements, however, this was 
not replicated for the MSD measurements. This is probably due to the nature of both methods and needs further 
validation. These observations might be relevant for evaluation of the clinical aspects of changes in brain IL-2 lev-
els. Nevertheless, the current study was not designed to address such issues as the sample size is a limiting factor. 
Due to our modest sample size included in this experimental setup, additional studies using larger cohorts are 
needed to validate these findings.
One regulator of IL-2 and T cell proliferation is GSK3B protein12. We identified increased mRNA levels of 
GSK3B in PSP brains. In the brain, GSK3B protein participates in the production of pro-inflammatory mediators 
secreted by microglia cells13. GSK3B has previously received considerable attention in relation to PSP as GSK3B 
protein activity mediates aggregation of tau14. However, interventional strategies targeting GSK3B have been 
unsuccessful15. Although mRNA and protein levels are not directly correlated, our findings are in addition to the 
previous observations of a central role of GSK3B in the brains of PSP patients.
For the first time, we report on lymphocyte populations in blood of PSP patients. IL-2 protein is produced 
by CD4+ and CD8+ T cells as well as CD56+ and CD57+ NK cells either as developing or mature cells8,16,17. 
Overall, the observed shift in the pool of T cells toward an increase in CD45RA−CD45RO+ memory T cells may 
be indicative of an active, adaptive immune response. Further, the concurrent decrease in CD45RA+CD45RO− 
naive T cells, accompanied by increased numbers of CD4+, but not CD8+, T cells, could be indicative of a pos-
sible reduced capacity of the adaptive immune system toward novel stimuli18. Lastly, the observed increase in 
CD56+ NK cells, but not of activated CD56+CD57+ NK cells, points toward an increased capacity to respond to 
innate immune challenges. These results are supported by the results from Santiago and Potashkin19 reporting on 
affected gene clusters in PSP that are overrepresented in biological pathways of both leukocyte and lymphocyte 
activation. Nevertheless, limitations to our study are the low number of individuals as well as the lack of demo-
graphic and clinical information for factors affecting peripheral lymphocyte levels. Therefore, we encourage that 
our observations should be validated in a separate study using a larger and well-defined cohort.
Lately, IL-2 has received much attention as an immune effector in AD since animal studies have shown a 
beneficial effect of IL-2 on amyloid pathology20,21. We could therefore speculate that the increased levels observed 
in the PSP brains are reflecting compensatory effects to the disease progression rather than necessarily being the 
cause of the detrimental effects. Therefore, IL-2 treatment aiming at specifically expanding and activating regula-
tory T cells recently proposed in AD22,23 could also be an interesting venue to explore in relation to PSP, which at 
present is a disease without curative treatment.
Other studies have reported on cytokine gene expression in several brain areas of PSP patients with differing 
results. One study observed increased expression of IL-1beta(β) in the substantia nigra and no change in the 
expression of transforming growth factor β in the frontal cortex of PSP patients7, whereas another study identified 
increased expression of the latter in the frontal cortex of PSP patients compared to controls6. In the current study, 
we did not assess protein levels of transforming growth factor β, nor did we investigate cytokine expression in the 
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substantia nigra. Here, we focused on the prefrontal cortex which is an area that is only mildly affected in PSP4. 
Our aim was to identify disease pathology distant to the epicenter of the disease that may reflect earlier stages 
of degenerative processes. This is a limiting factor to our study, and we can therefore not exclude that cytokine 
expression may be different in other more affected brain areas in PSP patients.
To conclude, in the present study we have identified and validated an increase in IL-2 protein levels in the 
prefrontal cortex of PSP patients compared with NCs. PSP thereby presents a similar cytokine profile as the 
Figure 2. T and NK cell populations in blood of PSP patients. We investigated peripheral blood mononuclear 
cells in a new cohort consisting of 18 normal controls and nine PSP patients. We investigated fractions of (A–G) 
T cells and (H–K) natural killer (NK) cells. For gating strategies, see Supplementary Figs. 1 and 2. Data are 
presented as mean ± SEM; n.s. non-significant; ***p < 0.001.
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one identified for both Parkinson’s disease and multiple system atrophy in the same brain area. Further, we 
have observed changes in the peripheral immune system. Our results are indicative of an active and dysregu-
lated adaptive and innate immune response. These data warrant future investigations into the possible role of the 
immune systems in PSP pathophysiology.
Materials and Methods
Patient material. The tissue for the present study originated from donated human brains. All donors pro-
vided written informed consent prior to death. PSP samples were analyzed alongside NC samples9. Brain samples 
were provided by the Bispebjerg Brain Bank (University Hospital of Copenhagen, Bispebjerg Hospital, DNK), the 
Netherlands Brain Bank (Netherlands Institute for Neuroscience, NLD), and the Harvard Brain Tissue Resource 
Center (Harvard Medical School Teaching Hospital, USA). A summary of demographic data for the 16 NC and 
16 PSP brain samples are shown in Table 3. All brains were neuropathologically examined to verify the clinical 
diagnosis1,24. Medical records were available for 13 of the 16 patients. The clinical characteristics are shown in 
Table 1. Clinical scorings were based on the clinicians’ notes as well as appropriate, clinical tests, e.g., the Mini-
Mental State Examination, the Montreal Cognitive Assessment, or the Addenbrooke's Cognitive Examination 
tests for dementia and cognitive dysfunction. All brain samples have been collected and handled in accordance 
with Danish ethical standards of the Brain Bank and the Danish Health and Medicine Authorities. Samples were 
stored at −80 °C prior to handling. Flow cytometry was performed on a new cohort of samples, that included 18 
NC and nine PSP samples, a summary of the demographic data are shown in Table 3. These samples were gen-
erously donated by Bispebjerg Movement Disorder Biobank. This project was approved by the Regional Ethics 
Committee of the Capital Region of Denmark (DNK), jr.no. H-16025210. All experiments have been performed 
in accordance with the Declaration of Helsinki25.
Protein analyses. Protein extraction and quantification of total levels were performed as earlier described9. 
In short, app. 50 mg brain tissue was disrupted and homogenized using a MagNA Lyzer Instrument (Roche 
Life Science) in a buffer containing protease inhibitors. Samples were spun to pellet cell debris. Sample concen-
trations were determined using the Bradford protein quantification assay26. The protein concentrations in the 
NC sample extracts (mean 3.61 ± SD 1.04 mg/ml) did not differ from the PSP sample extracts (mean 3.17 ± SD 
0.56 mg/ml; Welch’s unpaired t-test, t = 1.421, p = 0.171). All samples were aliquoted to avoid thawing prior to 
analysis. Cytokine and neurotrophin protein levels were investigated on a Bio-Plex Pro Human Cytokine 17-plex 
Assay (BIO-RAD, USA; #M5000031YV) which included antibodies for the targets interleukin(IL)-1β, IL-2, 
ILs 4–8, IL-10, IL-12, IL-13, IL-17, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage 
colony-stimulating factor, interferon-gamma, monocyte chemoattractant protein 1, macrophage inflamma-
tory protein(MIP)1β, and tumor necrosis factor(TNF)alpha(α). Further, the following singleplex targets were 
added to the assay: basic fibroblast growth factor (BIO-RAD; #171B5016M); MIP1α (BIO-RAD; #171B5022M); 
platelet-derived growth factor BB (BIO-RAD; #171B5024M); and vascular endothelial growth factor (VEGF; 
BIO-RAD; #171B5027M). The assays were analysed on a Bio-Plex 200 System (Luminex xMAP Technology, 
BIO-RAD) following the manufacturer’s instructions. Samples were added in a concentration of 1 mg protein/ml 
after 1:2 dilution in sample diluent.
Validation of IL-2 and G-CSF protein levels were investigated on MSD V-PLEX Human IL-2 Assays (Meso 
Scale Discovery (MSD), USA; #K151QQD; lower limit of detection (LLOD): 0.09 pg/ml) and MSD U-PLEX 
G-CSF Assays (MSD; #K151VGK; LLOD: 1.6 pg/ml), respectively, following the manufacturer’s instructions. 
Plates were analyzed on a SECTOR S 600 instrument (MSD).
mRNA analyses. Extraction, quality assessment of total RNA, DNA contamination, and analysis of mRNA 
levels was performed as previously described9. All RNA experiments were performed in accordance with the 
MIQE guidelines27. Extraction of RNA was performed using the miRNeasy Mini Kit (Qiagen, NLD; #217004). 
In short, app. 30 mg brain tissue was homogenized by intensive pipetting in a lysis reagent. Samples were then 
phase separated in chloroform, and subjected to on-column DNase treatment. Samples were eluted in 30 µl 









NC 6 BBH, 10 NBB 16 6M 10F 76.6 ± 10.9 5.2 ± 0.7 21.7 ± 20.9
PSP 13 BBH, 3 HV 16 12M 4F 73.6 ± 8.2 5.5 ± 2.4 31.2 ± 17.1 7.9 ± 3.1
p 0.080 0.198 0.420 0.131
PBMC
NC BMDB 18 14M 4F 70.1 ± 6.4
PSP BMDB 9 7M 2F 67.3 ± 7.9 7.3 ± 3.7
p >0.999 0.336
Table 3. Demographic overview of patient samples. NC: Normal controls; PSP: Progressive supranuclear palsy; 
BBH: Bispebjerg Brain Bank; BMDB: Bispebjerg Movement Disorder Biobank; NBB: Netherlands Brain Bank; 
HV: Harvard Brain and Tissue Resource Center; M: Male; F: Female; RIN: RNA Integrity Number; PMI: Post-
mortem interval; DD: Disease duration; PBMC: Peripheral blood mononuclear cells. Age and DD are shown in 
years, PMI is shown in hours. Age, RIN, PMI and DD are shown as mean ± standard deviation. DD is defined as 
time from first symptoms to death. P values for group differences are shown on the bottom.
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nuclease-free water. RNA integrity was measured using the Agilent RNA 6000 Nano Kit (Agilent Technologies, 
USA; #5067-1511) on an Agilent 2100 Bioanalyzer (Agilent Technologies). All samples had a RIN >  3.95 as 
suggested earlier28,29. DNA contamination was investigated using primers for glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH). cDNA synthesis was performed using qScript (Quanta BioSciences, USA; #95048) with 
100 ng input RNA. cDNA concentrations were measured on a NanoDrop 2000C (Thermo Fisher Scientific), 
and diluted to 100 ng/µl in nuclease-free water. RT-qPCR was performed with SYBR Green Master Mix 2X 
(Thermo Fischer Scientific; #4309155) on a Stratagene Mx3005P qPCR system, or a QuantStudio 3 Real-Time 
PCR System (Thermo Fischer Scientific). All primers had an efficiency of 93–108% with an R2 > 0.98. Primer 
concentrations ranged from 300 to 500 nM with an annealing temperature of 56–62 °C. An acquisition step was 
added when necessary at 77–80 °C. The amplicons were 72 to 146 base pairs long. A melting curve was included 
in each reaction for product verification. Targets of interest were: glycogen synthase kinase 3β (GSK3B), for-
ward primer: 5-ACAACAGTGGTGGCAACTCC-3, reverse primer: 5-TTCTTGATGGCGACCAGTTCT-329; 
nuclear factor kappa-light-chain-enhancer of activated B cells inhibitor alpha (NFKBIA), forward primer: 
5-AGCCTACAAGAAAGTTTGCCTAT-3, reverse primer: 5-TCTTCTTCCGGTAGTGGATCTTGGC-3; 
nuclear receptor subfamily 4 group A member 2 (NR4A2; also known as Nurr1), forward primer: 
5-CCGGGATCTCTCCACAACTT-3, reverse primer: 5-GGAGACTGGCGTTTTCCTCT-3; and transcrip-
tion factor p65 (RELA; also known as NFKB-p65), forward primer: 5-CTGCCGGGATGGCTTCTAT-3, 
reverse primer: 5-CCGCTTCTTCACACACTGGAT-330. A calibrator sample (cDNA from Human Reference 
Total RNA; Clontech, USA; #636538), was included on each plate31. Sample cycle threshold (Ct) values were 
normalized to the reference genes29: ubiquitin-conjugating enzyme E2D2 (UBE2D2), forward primer: 
5-TGCCTGAGATTGCTCGGATCT-3, reverse primer: 5-TCGCATACTTCTGAGTCCATTCC-332; 
ribosomal protein 13a (RPL13A), forward primer: 5-AGCCTACAAGAAAGTTTGCCTAT-3, reverse 
primer: 5-TCTTCTTCCGGTAGTGGATCTTGGC-3; and topoisomerase 1 (TOP1), forward primer: 
5-GGCGAGTGAATCTAAGGATAATGAA-3, reverse primer 5-TGGATATCTTAAAGGGTACAGCGAA-333. 
Normalized values were calculated using the geometric mean34.
Immunohistochemistry. Immunostainings on FFPE tissue samples were performed as previously 
described9. In short, brain samples from three PSP patients and three NCs containing both white and grey mat-
ter were excised and fixed in formalin for min. 48 h in 10% buffered formalin before embedding in paraffin on 
a Leica ASP300 S tissue processor (Leica, DEU). Samples were cut on a sliding microtome into 5 µm sections. 
All antibodies were tested alone using HRP and 3,3′-diaminobenzidine tetrahydochloride hydrate as previously 
described9. For immunofluorescent double labelling, slides were deparaffinized before antigen retrieval at pH 6 
(NeuN) and/or 9 (IL-2, GFAP) followed by incubation with primary antibodies: Monoclonal rabbit anti-human 
IL-2 (1:250; Abcam; #ab92381), and monoclonal mouse anti-human NeuN (1:500; Merck Millipore; #MAB377) 
or monoclonal mouse anti-human GFAP (1:200; Dako; #M0761). Secondary antibodies were goat anti-mouse 
IgG Alexa Fluor 488 (1:200; Invitrogen; #A11001) and goat anti-rabbit IgG TRITC (1:1000; Abcam; #ab6718). 
Cover slides were mounted with medium containing DAPI. Stainings were investigated using a Nikon Eclipse 
80i microscope. Specificity of the IL-2 antibody was tested on tonsils as a positive control (data not shown). 
Additionally, appropriate isotype controls were included to verify specificity.
Flow cytometry. Blood was collected in 9 ml EDTA tubes (Greiner Bio-One; #455036). Briefly, blood was 
diluted 1:1 in Dulbecco’s PBS (DPBS; Sigma-Aldrich; #D8537) containing 2 mM EDTA (Sigma-Aldrich; #E9884) 
and 1:5 in a Ficoll-Paque PLUS gradient (GE Healthcare Life Science; #17144003). Cells were washed twice with 
PBS and frozen in RPMI-1640 (Sigma-Aldrich; #R5885) containing 40% fetal calf serum (FCS; Gibco; #26010-
074) and 10% dimethyl sulfoxide (Sigma-Aldrich; #D4540) in cryotubes at −80 °C in a Mr. Frosty Freezing 
Container (Thermo Scientific), then stored at −130 °C until use.
On the day of analysis, PBMCs were thawed at 37 °C for 10 min before washing in 10% FCS in RPMI-1640 fol-
lowed by centrifugation at 200 g for 10 min. 200,000 cells were added to a well on a round bottom plate. The plate 
was spun down at 2,600 RPM for 2 min before washing in 1X Foxp3 TF Wash Buffer (Invitrogen; A24261) in 1% 
BSA (Sigma-Aldrich; #05482) in PBS followed by another spin down. Cells were incubated for 30 min in the dark 
at 4 °C in 45 µl antibody staining solution. The staining solution contained antibodies against TCR-α/β (1:8; BD 
Biosciences; #555548), CD3ε (1:50; BioLegend; #300431), CD4 (1:50; BD Biosciences; #564976), CD8 (1:50; BD 
Biosciences; #565310), CD14 (1:25; BioLegend; #325618), CD16 (1:25; BioLegend; #302012), CD45R0 (1:50; BD 
Biosciences; #562327), CD45RA (1:50; BD Biosciences; #563963), CD56 (1:25; BioLegend; #318334), and CD57 
(1:25; BD Biosciences; #561906) in Brilliant Stain Buffer (BD Biosciences; #563794). Cells were washed in 180 µl 
1X Foxp3 TF Wash Buffer and centrifuged at 600 × g for 5 min before 150 µl 1X Fixation and Permeabilization 
Solution (Buffer A: Invitrogen; #A24217; Buffer B: Invitrogen; #A24218) was added for 15 min at room tempera-
ture. After centrifugation at 600 × g for 5 min, cells were resuspended in 200 µl 1% BSA in PBS for analysis.
Samples were quantified on a BD LSR II flow cytometer (BD Biosciences). A minimum of 20,000 events were 
counted per sample. Data were analyzed using FlowLogic v. 7.2.1 (Inivai Technologies). The gating strategies are 
illustrated in Supplementary Figs. S1 and S2 which are based on compensation and FMO analyses.
Statistics. ILs 4, 5, 8, 10, 12, 17, MIP1α, TNFα and VEGF proteins were omitted from the analyses as detec-
tion sensitivity was less than 50%. One sample did not present detectable protein levels in any measurements on 
the Luminex assays and was excluded from further analyses. For each target, samples that presented measure-
ments below the minimum detection limit were omitted from the analysis. Outliers were identified using the 
ROUT method with Q = 1% in GraphPad Prism v. 7.02 (GraphPad Software Inc., USA). Demographic data were 
analyzed using an unpaired t-test (age), a Mann-Whitney test (RNA Integrity Number (RIN) and post-mortem 
interval (PMI)), or Fischer’s exact test (sex). Spearman’s Rank-Order Correlation test was applied to correlation 
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analyses of clinical characteristics and IL-2 protein levels. Student’s t-test or Welch’s t-test was used for flow 
cytometry analyses. The remaining statistical analyses were performed in R v. 3.4.135. Normality was assessed 
using the Shapiro-Wilk Normality test. Scedasticity and collinearity were assessed using ncvTest and vif, respec-
tively, from the car package36. If necessary, data were log10-transformed. Data were analyzed using multiple lin-
ear regression with models that included relevant variables that have previously been shown to possibly impact 
results9. These variables included group (NC vs. PSP), age, sex (female vs. male), and PMI as well as RIN for 
the mRNA targets. Familywise error rate was adjusted using Bonferroni correction for the multiplex data (adj. 
p = 4.17*10−3, n = 12). Graphs were made in GraphPad Prism v. 7.02.
Data Availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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